Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOS | P01100 | 1/20 | 0.71 |
| ▸ | TTR | P02766 | 1/20 | 0.71 |
| ▸ | JUN | P05412 | 1/20 | 0.71 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.71 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.71 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.71 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.65 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.65 |
| ▸ | MMP1 | P03956 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | ATM | Q13315 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3900627 | 1.00 | FOS (0.71) | FOSTTRJUNNR3C1HSD17B1 | |
| SCHEMBL2959285 | 0.87 | FOS (0.71) | FOSTTRJUNNR3C1HSD17B1 | |
| SCHEMBL5277797 | 0.87 | ALOX15 (0.71) | FOSTTRJUNNR3C1HSD17B1 | |
| SCHEMBL5277808 | 0.87 | ALOX15 (0.71) | FOSTTRJUNNR3C1HSD17B1 | |
| SCHEMBL8828295 | 0.85 | CA2 (0.60) | ALOX15ALOX12TAAR1ATM | |
| SCHEMBL30559576 | 0.85 | CA2 (0.60) | ALOX15ALOX12TAAR1ATM | |
| SCHEMBL1026086 | 0.85 | CA2 (0.60) | ALOX15ALOX12TAAR1ATM | |
| SCHEMBL1023836 | 0.85 | CA2 (0.60) | ALOX15ALOX12TAAR1ATM | |
| SCHEMBL16364799 | 0.84 | GAA (0.67) | FOSTTRJUNNR3C1HSD17B1 | |
| SCHEMBL19117433 | 0.84 | GAA (0.67) | FOSTTRJUNNR3C1HSD17B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220273680-A1 | Methods of Treating Psychological and Brain Disorders | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2022-09-01 | — | — | US | claimed |
| EP-4013403-A1 | METHODS OF TREATING PSYCHOLOGICAL AND BRAIN DISORDERS | University of Maryland, Baltimore (US) | 2022-06-22 | — | — | EP | claimed |
| WO-2021030571-A1 | METHODS OF TREATING PSYCHOLOGICAL AND BRAIN DISORDERS | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2021-02-18 | — | — | WO | claimed |
| EP-1701949-B1 | ASSAY FOR ENTACTOGENS | SIEMENS HEALTHCARE DIAGNOSTICS INC (US) | 2018-04-18 | — | — | EP | claimed |
| EP-1701948-B1 | ASSAY FOR ENTACTOGENS | SIEMENS HEALTHCARE DIAGNOSTICS (US) | 2014-03-26 | — | — | EP | claimed |
| US-20090280499-A1 | METHOD AND KIT FOR DETECTING, OR DETERMINING 3,4- METHYLENEDIOXYMETHAMPHETAMINE | RANDOX LABORATORIES LIMITED (GB) | 2009-11-12 | — | — | US | claimed |
| EP-1701948-A4 | ASSAY FOR ENTACTOGENS | SIEMENS HEALTHCARE DIAGNOSTICS (US) | 2009-03-04 | — | — | EP | claimed |
| EP-1701949-A4 | ASSAY FOR ENTACTOGENS | DADE BEHRING INC (US) | 2008-02-20 | — | — | EP | claimed |
| EP-1701948-A1 | ASSAY FOR ENTACTOGENS | DADE BEHRING INC. (US) | 2006-09-20 | — | — | EP | claimed |
| EP-1701949-A2 | ASSAY FOR ENTACTOGENS | DADE BEHRING INC. (US) | 2006-09-20 | — | — | EP | claimed |
| US-6991911-B2 | Assay for entactogens | DADE BEHRING INC. (US) | 2006-01-31 | — | — | US | claimed |
| US-6946547-B2 | Ecstasy-class analogs and use of same in detection of ecstasy-class compounds | MICROGENICS CORPORATION (US) | 2005-09-20 | — | — | US | claimed |
| WO-2005058864-A1 | ASSAY FOR ENTACTOGENS | DADE BEHRING INC. (US) | 2005-06-30 | — | — | WO | claimed |
| WO-2005058865-A2 | ASSAY FOR ENTACTOGENS | DADE BEHRING INC. (US) | 2005-06-30 | — | — | WO | claimed |
| US-20050130243-A1 | Assay for entactogens | SIEMENS HEALTHCARE DIAGNOSTICS INC. | 2005-06-16 | — | — | US | claimed |
| US-20050130244-A1 | for detection of 3,4-methylenedioxyamphetamine (MDA), 3,4-methylenedioxy-methamphetamine (MDMA) anibody production; drug screening; haptens; immunogens | SIEMENS HEALTHCARE DIAGNOSTICS INC. | 2005-06-16 | — | — | US | claimed |
| US-20030207469-A1 | Ecstasy-class analogs and use of same in detection of ecstasy-class compounds | MICROGENICS CORPORATION (US) | 2003-11-06 | — | — | US | claimed |
| US-20260102372-A1 | NEW FORMULATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT | TACTOGEN INC (US) | 2026-04-16 | — | — | US | disclosed |
| EP-1167976-A2 | Immunoassay for the detection of amphetamines and derivatives thereof | BOEHRINGER MANNHEIM GMBH (DE) | 2002-01-02 | — | — | EP | disclosed |
| WO-1994000432-A1 | ANORECTIC EPINEPHRINE DERIVATIVES | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1994-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207469-A1 | Ecstasy-class analogs and use of same in detection of ecstasy-class compounds | CES2, DNPEP, HLA-A | FOS 3019/4885TTR 4666/4885JUN 4352/4885 |
| US-20090280499-A1 | METHOD AND KIT FOR DETECTING, OR DETERMINING 3,4- METHYLENEDIOXYMETHAMPHETAMINE | KIT, PNMT, HNMT | FOS 2193/4885TTR 4127/4885JUN 3613/4885 |
| US-20050130243-A1 | Assay for entactogens | HTR3C, COMT, PNMT | FOS 4497/4885TTR 3253/4885JUN 4763/4885 |
| US-20260102372-A1 | NEW FORMULATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT | SLC6A4, SLC6A2, SLC6A3 | FOS 1379/4885TTR 617/4885JUN 1228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.